Compare ADMA Biologics Inc (ADMA) vs Crowdstrike Holdings Inc (CRWD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Crowdstrike Holdings Inc — how do they compare? ADMA Biologics Inc trades at $9.86 (market cap $2.22B), while Crowdstrike Holdings Inc trades at $221.32 (market cap $225.95B). The key difference: Crowdstrike Holdings Inc is far larger — about 101.8× ADMA Biologics Inc's market cap, and Crowdstrike Holdings Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | CRWD | |
|---|---|---|
Market Cap | $2.22B | $225.95B |
Sector | Health | Technology |
52-Week High | $20.38 | $225.16 |
52-Week Low | $7.60 | $87.56 |
Enterprise Value | $2.29B | $222.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
CrowdStrike (CRWD) trades at $221.01, down 1.84% today, but maintains a strong technical uptrend with bullish moving averages and support at $219. The stock has delivered consistent earnings beats, with Q1 2026 EPS of $0.28 exceeding the $0.27 estimate. Revenue growth remains robust, climbing to $3.95 billion in 2025, though net margins are slightly negative. Recent positive news includes being named a leader in IDC's MDR/MXDR report (Business Wire, August 11, 2026) and surging cybersecurity sector interest.
Outlook is cautiously optimistic given strong revenue expansion and platform adoption, but high valuation multiples (P/E 765.02, P/S 44.07) pose risks. Analyst consensus is bullish with 76% buy ratings and a $191.74 price target, though current price exceeds this. Key risks include premium valuation sensitivity, competitive pressures, and macroeconomic impacts on tech spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →
